Myla Health’s menopause service is notable for describing what happens around the appointment: a consultation summary, communication with a GP and a later review. Those steps matter when a hormone plan contains medicines with different purposes. They also expose an important distinction between recommending a plan and another clinician agreeing to continue it.
We reviewed Myla’s services, current pricing and detailed FAQ on September 29, 2026. These pages verify a UK clinical service, not unrestricted international telemedicine. They do not establish a particular oral progesterone product for a reader. This review examines the published handoff and review process without assuming a personal treatment goal or a complete assessment of records that have not been seen.
The service begins with a defined appointment
Myla’s service description gives an initial forty-five-minute face-to-face or video consultation, covering symptoms and options before a private prescription or a letter to the GP. Its FAQ requires the patient to be on UK soil at the time of the consultation and to have a UK address for medication delivery. A video option therefore does not imply US access or overseas supply. Newson Clinic provides another UK consultation comparison. A relevant service is established in both cases, but an appointment category cannot determine the reason an individual should receive progesterone or confirm the exact preparation offered.
The written summary can make each purpose explicit
The published pathway says a consultation summary is sent to the patient and GP within the following week. That is a provider commitment described on its site, not a response time tested by this review. A useful summary would distinguish the problem being treated from any separate reason for an additional medicine. The systemic estrogen guide explains that those aims need not be identical. NICE’s clinical guidance supplies general context for discussing treatment in relation to history; it does not prove what a Myla letter contains. A reader can ask for clarification if a medicine is named without its intended role being understandable.
Uploaded records are not automatically reviewed records
Myla’s FAQ states that uploaded documents are not guaranteed to be reviewed before the appointment. It also limits responsibility for outside investigations to those the clinician has formally reviewed and interpreted, directing urgent test concerns to the professional who ordered them. That is an important boundary for anyone expecting an old surgical or laboratory record to speak for itself. ACOG’s description of different hysterectomy procedures shows why the detail can matter. The hysterectomy-history guide supports asking which records are relevant and whether they have actually been considered, without turning a past operation into a self-directed treatment rule.
A GP letter is a recommendation, not an NHS guarantee
The FAQ explains that private prescriptions are handled through Pharmacierge and that recommendations can be sent to the patient’s GP. Local NHS formularies may affect availability, and the GP is not obliged to prescribe the recommended treatment. These are distinct routes, with different responsibilities and potential charges. Myla says it uses regulated body-identical HRT rather than compounded preparations, but this still does not identify a supplied oral progesterone product. Defy Medical’s review provides a US comparison in which similar-looking hormone language sits within a different care system. A handoff requires agreement about who continues prescribing and who reassesses the plan.
The consultation fee excludes the pharmacy bill
Myla’s prices effective April 1, 2026 list £290 for the forty-five-minute initial visit and £190 for a thirty-minute follow-up. Prescription administration is free during the first three months; medicine is paid for separately through the pharmacy, and a £35 administration fee applies to later prescription requests outside the included period. The service pathway describes a follow-up around three months as a further charged appointment. These amounts should not be summarized as an all-inclusive hormone price. Before comparing services, the selected arrangement needs to distinguish appointments, administrative work and the actual medicine cost rather than treating the initial consultation as ongoing care. The FAQ requires payment at booking. It lists a 100% cancellation charge for less than twenty-four hours’ notice, and 50% for more than twenty-four hours but less than two working days. Another line says notice exceeding forty-eight hours incurs no fee. Those working-day and clock-hour statements leave a boundary to clarify with Myla; this review does not silently reconcile them.
Continued prescribing includes a review requirement
Myla’s FAQ says annual review is required if it continues prescribing; after more than eighteen months away, a new longer appointment is needed. Interim prescribing is conditional on clinical appropriateness and circumstances, not an automatic consequence of a payment. The service page distinguishes brief clarifications from questions needing a further consultation. The local vaginal estrogen guide illustrates one reason an apparently simple hormone question may require identifying the exact treatment context. These published service arrangements do not authorize a reader to extend, interrupt or change a prescription, and they do not establish what a clinician would decide after a change in history.
A changed symptom should not wait for an administrative answer
NHS advice is to have any postmenopausal vaginal bleeding checked, even a small one-off episode. The unexpected bleeding discussion keeps that assessment separate from a prescription request or question about appointment charges. Myla’s FAQ provides communication routes, but an email process should not be treated as a diagnosis or a guaranteed urgent response. The documented strengths of the offer are its defined visit and communication arrangements. What remains individual is the medicine’s purpose, the interpretation of history, the exact preparation and the professional accepting responsibility when care moves between a private clinic, pharmacy and NHS practice.
Sources behind this article
Use the original documents to check their scope. A provider’s offer and a named medicine’s label establish different facts.
- Myla Health: Our servicesUK provider consultation, written-summary and paid follow-up pathway; published arrangements are not tested service or response guarantees · Checked 2026-09-29
- Myla Health: Frequently asked questionsUK provider clinical, geographic, records-review, pharmacy, NHS handoff and follow-up conditions; no individual eligibility or later GP agreement inferred · Checked 2026-09-29
- NICE NG23: Menopause, identification and management — recommendationsUK clinical recommendations; systemic/local exposure, total hysterectomy and specialist-history qualifications are not provider-specific protocol or personal treatment directions · Checked 2026-09-29
- ACOG: HysterectomyUS professional patient guidance, updated September 2024 and reviewed May 2025; distinguishes operative terms without inferring an individual operation or hormone need · Checked 2026-09-29
- Myla Health: PricingUK provider prices effective April 1, 2026; consultation, prescription administration and separate pharmacy medicine costs retain their published units · Checked 2026-09-29
- NHS: Postmenopausal bleedingUK public patient guidance, reviewed September 24, 2026; bleeding assessment advice does not diagnose a cause or transfer NHS referral timings to US services · Checked 2026-09-29